Jafron Biomedical Co.,Ltd. (300529.SZ)
- Previous Close
21.80 - Open
22.06 - Bid 21.92 x --
- Ask 21.93 x --
- Day's Range
21.72 - 21.98 - 52 Week Range
21.12 - 39.24 - Volume
4,889,026 - Avg. Volume
7,752,533 - Market Cap (intraday)
17.513B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
23.58 - EPS (TTM)
0.93 - Earnings Date --
- Forward Dividend & Yield 0.40 (1.83%)
- Ex-Dividend Date May 31, 2024
- 1y Target Est
29.10
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption field in worldwide. The company provides solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases. It offers HA series hemoperfusion cartridge, BS series bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, disinfectants, hemodialysis concentrate, resin bandages, online hemodialysis powder bag/bucket, and adsorbable suture with needles, as well as syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
www.jafroninternational.comRecent News: 300529.SZ
View MorePerformance Overview: 300529.SZ
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300529.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300529.SZ
View MoreValuation Measures
Market Cap
17.41B
Enterprise Value
16.23B
Trailing P/E
23.40
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.86
Price/Book (mrq)
4.93
Enterprise Value/Revenue
6.54
Enterprise Value/EBITDA
17.02
Financial Highlights
Profitability and Income Statement
Profit Margin
29.19%
Return on Assets (ttm)
9.57%
Return on Equity (ttm)
21.24%
Revenue (ttm)
2.48B
Net Income Avi to Common (ttm)
724.21M
Diluted EPS (ttm)
0.93
Balance Sheet and Cash Flow
Total Cash (mrq)
2.59B
Total Debt/Equity (mrq)
39.89%
Levered Free Cash Flow (ttm)
351.56M